Objective Chemoradiotherapy is often considered the ‘standard of care’ for patients with N2 disease. The aim was to evaluate survival outcomes of patients with N2 disease in multimodality trials of chemotherapy, radiotherapy and surgery.
Methods Systematic review and meta-analyses (random and fixed effects) were performed. Searches of Medline and Embase (1980–2013) were conducted. Abstracts from thoracic scientific meetings were searched. Reference lists of all relevant studies were reviewed. All studies of patients with N2 disease who received induction chemotherapy or chemoradiotherapy and randomised to surgery or radiotherapy were included. No language restrictions were imposed. The main outcome was overall survival.
Results 805 publications were identified. 519 and 281 were excluded because they were not primary results from randomised trials (or did not include N2 disease) or did not compare surgery with radiotherapy, respectively. The final six trials consisted of 868 patients. In four trials, patients received induction chemotherapy and in two trials patients received induction chemoradiotherapy. The HR comparing patients randomised to surgery after chemotherapy was 1.01 (95% CI 0.82 to 1.23; p=0.954) whereas for patients randomised to surgery after chemoradiotherapy was 0.87 (0.75 to 1.01; p=0.068). The overall HR of all pooled trials was 0.92 (0.81 to 1.03; p=0.157).
Conclusions Surgery should be considered as part of multimodality treatment for patients with resectable lung cancer and ipsilateral mediastinal nodal disease. In trials where patients received surgery as part of trimodality treatment, overall survival was better than chemoradiotherapy alone.
- Thoracic Surgery
- Lung Cancer
- Lung Cancer Chemotherapy
Statistics from Altmetric.com
What is the key question?
Should surgery be considered as part of multimodality treatment for patients with resectable lung cancer and ipsilateral mediastinal nodal disease?
What is the bottom line?
In trials where patients received surgery as part of trimodality treatment, overall survival was better than chemoradiotherapy alone.
Why read on?
This systematic review and meta-analyses suggests no important differences in overall survival in patients randomised to surgery as part of bimodality treatment and improved survival in patients randomised to surgery as part of trimodality treatment.
Lung cancer is often cited as the largest cause of cancer deaths worldwide.1 Surgery is often considered to be the treatment of choice,2 but the majority of patients present with disease that is too advanced. In the UK, the current lung cancer resection rate is 21%,3 a figure that is reflective of selection based on comorbidity and stage.
The International Association for the Study of Lung Cancer registry reported that 21% of patients with lung cancer present with clinical N2 disease. This subgroup of patients is heterogeneous by definition and surgical treatment (alone) is often considered controversial with a published 5-year survival rate in this subgroup of 25%.4 Specifically, the lung cancer community is divided on the optimum management of patients with a resectable primary tumour, without distant metastases, but with evidence of ipsilateral mediastinal non-fixed, non-bulky lymph node (N2) disease.
The ‘standard of care’ is often considered to be platinum-based chemoradiotherapy despite clinical trials conducted to evaluate the role of surgery as part of multimodality treatment due to difficulties in the interpretation of the available data. The conduct and reporting of the trials have been varied with two broad designs evaluating bimodality treatment (chemotherapy and either radiotherapy or surgery) and surgery as part of trimodality treatment (chemoradiotherapy and either surgery or not). A number of trials reported marginal effects in favour of surgery that were neither statistically significant nor considered to be clinically important differences.5
The aim of this study is to evaluate the role of surgery in patients with N2 disease as part of bimodality and trimodality treatment in the pooled results of published clinical trials with respect to overall patient survival.
We performed a systematic literature search of Medline (1980–2013) and Embase (1980–2013). To achieve the maximum sensitivity of the search strategy and identify all trials of patients with N2 disease, we used appropriate free text and thesaurus terms including among others ‘Non-Small Cell Lung Carcinoma’, non-small cell lung cancer and N2 (see online supplementary appendix A or the full search strategy can be obtained from EJ on request). We searched trial registers on the Internet. In order to locate unpublished work, abstracts from recent major thoracic surgery scientific meetings were searched. Reference lists of all relevant studies were reviewed and no restrictions were placed on language in any of the searches.
Study selection and data abstraction
All studies that included patients with non-small cell lung cancer and N2 disease were included. No restrictions were placed on abstracts, conference proceedings or language. Our exclusion criteria were studies that were not randomised, studies that were not confined to N2 disease and studies that did not compare surgery with radiotherapy after induction treatment.
Each individual trial was evaluated on the Downs and Black quality assessment tool,6 a list of 27 criteria that evaluates study reporting, external and internal validity, and has been ranked among the top six quality assessment scales suitable for use in systematic reviews.7
Two investigators (PJM, EL) assessed the papers separately according to the predetermined eligibility criteria and any discrepancies were then resolved by consensus. Percentages were converted into whole numbers for the purpose of reporting and analyses.
Where published, HRs for overall and disease-free survival were extracted directly from the manuscript. Where HRs were not reported, they were calculated from published summary statistics or survival plots using the method of Parmar (FS and EL).8
Random effects meta-analysis was performed by combining the results of reported or calculated individual trial HRs comparing surgery with radiotherapy. For sensitivity analyses, we repeated the estimates obtained by fixed effects meta-analysis and also by excluding the trial of induction chemoradiotherapy.
Statistical heterogeneity of trial results were tested using the χ2 test of homogeneity and also expressed as I2: the percentage of total variability attributed to the individual trials as a measure of inconsistency between studies (a value of 50% is regarded moderate).9 Statistical analyses were performed using Stata V.10.0 (StataCorp, College Station, Texas, USA). This work was performed without any funding.
Trial flow, characteristics and quality appraisal
Our search strategy identified 805 publications, of which five potentially relevant trials were included.10–14 In total, 389 were excluded because they were not clinical trials or did not include the N2 disease as the sole population, and 281 trials were excluded because they did not compare surgery with radiotherapy as the sole treatment modalities.
Downs and Black assessment was performed for all manuscripts that have been published, with a higher score indicating studies of higher reporting quality. The overall mean (SD) score was 22(3) out of a maximum of 33.
For the primary outcome of overall survival in trials of bimodality treatment, the pooled HR for death in the surgery group was 1.01 (95% CI 0.82 to 1.23; p=0.954), with no statistical evidence of heterogeneity (I2=0%, p=0.830), while for the primary outcome of overall survival in trials of surgery as part of trimodality treatment, the pooled HR for death in the surgery group was 0.87 (CI 0.75 to 1.01; p=0.068), again with no statistical evidence of heterogeneity (I2=0%, p=0.976).
Overall, the pooled HR for death in all bimodality and trimodality treatment trials (figure 2) for death in the surgical arm was 0.92 (0.81 to 1.03; p=0.157), again with no statistical evidence of heterogeneity (I2=0%, p=0.818).
Sensitivity analysis was performed by repeating the primary analysis using fixed effects model with exactly the same result and heterogeneity estimates.
There is no area in the management of lung cancer where there is more evidence and less consensus than the subgroup of patients with resectable primary disease in the presence of non-fixed, non-bulky N2 metastases. Considerable confusion arises in the optimum pathway for staging as well as treatment selection across the lung cancer guidelines in USA,15 Europe16 and the UK.17
While there are many different recommendations for confirmatory staging or induction treatment and restaging, few appreciate that the fundamental reason for confirmatory mediastinal lymph node staging is to select patients for surgery. This in turn, is based on a prevailing view that surgery is inappropriate for patients with N2 disease. If the lung cancer community was open to surgery as a valid treatment option for patients with N2 disease, from the outset, no further staging (Endobronchial ultrasound (EBUS) and transbronchial needle aspiration (TBNA) or mediastinoscopy and lymph node biopsies) would be recommended even if PET-CT suggests N2 positive disease.
The results of the pooled analyses of the available randomised trials to date suggest that surgery should be considered an option from the outset either as part of bimodality or trimodality management. In the bimodality trials, there was no difference in overall survival, so we would argue that both surgery and radiotherapy options are equally valid, and certainly in this setting where clinical equipoise exists (or rather when data suggest that clinical equipoise should exist), the appropriate selection of local treatment should be focused on the preference of a fully informed patient.18
In the trimodality setting, the results support surgery as part of multimodality management. We recognise that conventional levels of statistical significance was not achieved (P=0·068) but analysis of the point estimate and CIs suggests a distinct possibility of 13% relative improvement in overall survival. Moreover, the results of Albain et al reported a significant improvement in disease-free survival in patients who were randomised to surgical trimodality treatment. While we were not able to include a subanalysis of the disease-free survival by Sorensen et al,19 we would be very surprised if conventional levels of statistical significance could not be achieved.
This is a cohort of patients and, as a result, a group of studies that can be difficult to compare. Indeed, there have also been changes in the investigation of these patients over the past several years including the introduction of Positron Emission Tomography scanning and Endobronchial Ultrasound in the post induction setting. Further, all the pooled trials to date did not distinguish between single node/zone and multi-node/zone involvement and, therefore, we were not able to comment on this distinction. In our opinion, therefore, there should be no clinical distinction (as the trials included patients with multi-node/station involvement). In the Albain trial, 22% of patients enrolled had two or more stations involved. Finally, trials did not always comment on the proportion of lobectomies and pneumonectomies performed in the surgical arm and hence we were not able to undertake such a subanalysis.
Although chemoradiotherapy has long been considered to be the standard of care in patients with clinical N2 disease,2 the result of our systematic review and meta-analyses suggests no important differences in overall survival in patients randomised to surgery as part of bimodality treatment and improved survival in patients randomised to surgery as part of trimodality treatment. Therefore, in patients with a resectable primary tumour and ipsilateral non-bulky mediastinal lymph node disease, the management of choice should be surgery as part of trimodality treatment or either surgery or radiotherapy as part of bimodality management.
Surgery should be considered as part of multimodality treatment for patients with resectable lung cancer and non-bulky ipsilateral mediastinal lymph node disease. Although the overall survival of patients randomised to surgery in bimodality treatment was the same as that in medical treatment, in trials where patients who received surgery as part of trimodality treatment, the overall survival was better than that in chemoradiotherapy alone.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Contributors PJM: Acquisition, analysis and interpretation of the data, drafting and revising the manuscript, final approval of the submitted version and agreement to be accountable for all aspects of the work. AC: Acquisition, analysis and interpretation of the data, drafting and revising the manuscript, final approval of the submitted version and agreement to be accountable for all aspects of the work. EJ: Acquisition, analysis and interpretation of the data, drafting and revising the manuscript, final approval of the submitted version and agreement to be accountable for all aspects of the work. FS: Design of the work, data analysis, drafting and revising the manuscript, final approval of the submitted version and agreement to be accountable for all aspects of the work. EL: Conception and design of the work, analysis and interpretation of the data, drafting and revising the manuscript, final approval of the submitted version and agreement to be accountable for all aspects of the work.
Competing interests All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare no support from any organisation for the submitted work. PM, AC, EJ and FS have no financial relationships with any organisation that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work. EL reports personal fees from Abbott Molecular, personal fees from Glaxo Smith Kline, personal fees from Pfizer, personal fees from Norvatis, Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela and grants and personal fees from ScreenCell, outside the submitted work; and he is the founder of Informative Genomics, a blood based molecular diagnostic company based in London.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. EL (corresponding author) affirms that the manuscript is an honest, accurate and transparent account of the study being reported and that no important aspects of the study have been omitted.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.